Veru (NASDAQ:VERU) & Verano (OTCMKTS:VRNOF) Head-To-Head Contrast

Veru (NASDAQ:VERU) and Verano (OTCMKTS:VRNOF) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their risk, earnings, dividends, analyst recommendations, institutional ownership, valuation and profitability.

Institutional & Insider Ownership

47.2% of Veru shares are owned by institutional investors. Comparatively, 9.0% of Verano shares are owned by institutional investors. 15.2% of Veru shares are owned by company insiders. Comparatively, 9.1% of Verano shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Valuation & Earnings

This table compares Veru and Verano”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Veru	$16.89 million	2.56	-$22.73 million	($2.20)	-1.22
Verano	$878.59 million	0.52	-$341.86 million	($0.98)	-1.29

Veru has higher earnings, but lower revenue than Verano. Verano is trading at a lower price-to-earnings ratio than Veru, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a breakdown of current ratings and price targets for Veru and Verano, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Veru	1	0	3	0	2.50
Verano	1	0	0	1	2.50

Veru currently has a consensus target price of $22.50, indicating a potential upside of 736.43%. Given Veru’s higher possible upside, research analysts clearly believe Veru is more favorable than Verano.

Profitability

This table compares Veru and Verano’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Veru	N/A	-119.51%	-74.98%
Verano	-41.68%	-9.54%	-4.51%

Volatility & Risk

Veru has a beta of -1.42, meaning that its stock price is 242% less volatile than the S&P 500. Comparatively, Verano has a beta of 0.87, meaning that its stock price is 13% less volatile than the S&P 500.

Summary

Veru beats Verano on 8 of the 14 factors compared between the two stocks.

About Veru

Veru Inc., a late clinical stage biopharmaceutical company, focuses on developing medicines for treatment of metabolic diseases, oncology, and acute respiratory distress syndrome (ARDS). Its marketed products comprise FC2 female condom for the dual protection against unplanned pregnancy and the transmission of sexually transmitted infections. The company’s development program includes enobosarm, a selective androgen receptor modulator for treatment of augment fat loss and to prevent muscle loss in sarcopenic obese and overweight elderly patients; Enobosarm, a selective androgen receptor modulator for the treatment of AR+ ER+ HER2- metastatic breast cancer; and sabizabulin, a microtubule disruptor for the treatment of hospitalized patients with viral lung infection on oxygen support who are at high risk for viral induced ARDS and death. The company was formerly known as The Female Health Company and changed its name to Veru Inc. in July 2017. Veru Inc. was incorporated in 1971 and is headquartered in Miami, Florida.

About Verano

Verano Holdings Corp. operates as a vertically integrated multi-state cannabis operator in the United States. The company engages in the cultivation, processing, wholesale, and retail distribution of cannabis in Arizona, Arkansas, Connecticut, Florida, Illinois, Maryland, Massachusetts, Michigan, Nevada, New Jersey, Ohio, Pennsylvania, and West Virginia. It offers cannabis products under the Encore, Avexia, MUV, Savvy, BITS, and Verano brands for medical and adult-use markets. The company is headquartered in Chicago, Illinois.